Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
GlobeNewswire
– After six months of additional follow-up, clinical benefit rate (63%), overall response rate (41.9%), median progression-free..